Description
Foundayo Tablets (Orforglipron) — Now MHRA Approved, August 2026
Foundayo is a once-daily oral tablet form of orforglipron, a non-peptide GLP-1 receptor
agonist licensed for weight management alongside a reduced-calorie diet and increased
physical activity, and for improving blood sugar control in adults with type 2 diabetes.
Approved by the MHRA on 10 August 2026, it made the UK the first country in Europe to
license the medication. Developed by Eli Lilly the – company behind Mounjaro. Foundayo
is a small-molecule GLP-1 medicine rather than a modified copy of the natural hormone,
which is part of why it can be manufactured and absorbed as an ordinary tablet, with no
fasting or water rules.
How Does It Work?
Orforglipron mimics the action of GLP-1, a hormone released by the gut after eating, by
binding to and activating the same receptor in the body. It acts on appetite centres in the
brain to reduce hunger and food cravings, increases feelings of fullness, and helps people
eat less as a result. In people with type 2 diabetes, it also helps lower blood sugar when
levels are high. Unlike the Wegovy pill, Foundayo is not a modified peptide protected by an
absorption enhancer, as a small molecule, it can be taken at any time of day, with or
without food or water.
How Effective Is It?
The MHRA approval draws on the Phase 3 ATTAIN clinical trial programme.
- ATTAIN-1 (adults with obesity/overweight, without diabetes): at 72 weeks,
participants on the highest dose lost an average of approximately 12.4% of body
weight, versus approximately 0.9% with placebo. Around 59.6% of participants on the
highest dose lost at least 10% of their body weight, and 39.6% lost at least 15%. - ATTAIN-2 (adults with obesity/overweight and type 2 diabetes): at 72 weeks, the
highest dose produced an average weight reduction of approximately 9.6%, versus
approximately 2.5% with placebo, alongside meaningful improvements in blood sugar
control (HbA1c).
Weight loss with Foundayo has generally been more modest than with the highest doses of
injectable GLP-1 medicines, but it offers a needle-free, once-daily alternative with fewer
administration rules than other oral GLP-1 tablets.
Ingredients and Composition
Active Ingredient
Orforglipron — a non-peptide, small-molecule GLP-1 receptor agonist, believed to be
available in a titrating range of strengths (starting around 0.8 mg, with maintenance doses up
to approximately 17.2 mg) as the dose is increased gradually to manage tolerability.
Formulation
Because orforglipron is a small molecule rather than a peptide, it does not require the
absorption-enhancing technology used in some other oral GLP-1 tablets, which is part of
why it can be taken without fasting or water restrictions. Full inactive ingredient information
and confirmed UK strengths will be published when UK prescribing information is finalised at
launch.
Common Side Effects of Foundayo
Side effects are expected to be broadly similar to other GLP-1 medicines, and are largely
gastrointestinal. They tend to be dose-related and often ease as the body adjusts, which is
why the dose is increased gradually.
Common Side Effects
- Nausea
- Vomiting
- Â Diarrhoea
- Constipation
- Stomach pain, indigestion, bloating, reflux
- Reduced appetite
- Headache
- Fatigue
Serious Side Effects (Rare but Important)
- Pancreatitis – Severe and persistent stomach pain, with or without vomiting
- Gallbladder problems – Gallstones, sometimes linked to rapid weight loss
- Â Dehydration – Dizziness, fainting, very dark urine, or not passing urine
- Â Severe allergic reaction- Swelling of the face or throat, wheezing, or severe rash
- Low blood sugar – Mainly if used alongside insulin or a sulfonylurea in people with diabetes
If you experience any severe side effects, seek immediate medical attention.
Do Not Use If:
- You are allergic to orforglipron or any ingredients in the product
- You are pregnant, breastfeeding, or think you may be pregnant
- You have a personal or family history of certain thyroid cancers, or other conditions
your prescriber advises against it for
(This list is a general guide, always check the full Patient Information Leaflet and speak to
a prescriber about your individual medical history before starting treatment.)
Frequently Asked Questions
Everything you need to know about Foundayo, how it works and what to expect.

